<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - POTASSIUM CHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>POTASSIUM CHLORIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#lessSuitableForPrescribing" data-toggle="tab">Less suitable for prescribing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of hypokalaemia (patients with normal diet)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2&#8211;4 g daily in divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Electrolyte imbalance</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Dose dependent on deficit or the daily maintenance requirements.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>





      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Smaller doses must be used in the prevention of hypokalaemia, to reduce the risk of hyperkalaemia.</p>
            </section>
        
            <section class="generalInformation">
              <p>Avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Plasma-potassium concentration above 5&#8239;mmol/litre</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> abdominal pain, diarrhoea, flatulence, nausea, vomiting,
              </p>
              <p>
                <strong>notKnown:</strong> heart toxicity (with rapid infusion), bleeding (<i>with modified-release preparations</i>), gastro-intestinal obstruction (<i>with modified-release preparations</i>), ulceration (<i>with modified-release preparations</i>),
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Potassium chloride concentrate must be diluted with <b>not less</b> than 50 times its volume of sodium chloride intravenous infusion 0.9% or other suitable diluent and <b>mixed well</b>.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Ready-mixed infusion solutions should be used where possible; alternatively, potassium chloride concentrate as ampoules containing 1.5&#8239;g (K<sup>+</sup> 20&#8239;mmol) in 10&#8239;mL, is <b>thoroughly mixed</b> with 500&#8239;mL of sodium chloride 0.9% intravenous infusion and given slowly over 2 to 3 hours with specialist advice and ECG monitoring in difficult cases.</p><p>For <i>peripheral intravenous infusion</i>, the concentration of potassium should not usually exceed 40&#8239;mmol/L.</p><p>Higher concentrations of potassium chloride may be given in very severe depletion, but require specialist advice.</p>
            </section>
            <section class="directionsForAdministration">
              <p>Potassium salts are preferably given as a liquid (or effervescent) preparation, rather than modified-release tablets; they should be given as the chloride (the use of effervescent potassium tablets BPC 1968 should be restricted to <i>hyperchloraemic</i> states).</p>
            </section>
            <section class="directionsForAdministration">
              <p>Modified-release tablets should be swallowed whole with fluid during meals while sitting or standing.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Salt substitutes</h3>
              <p>A number of salt substitutes which contain significant amounts of potassium chloride are readily available as health food products (e.g. <i>LoSalt</i>
            <tm tmtype="reg"/> and <i>Ruthmol</i>
            <tm tmtype="reg"/>). These should not be used by patients with renal failure as potassium intoxication may result.</p>
            </section>
            <section class="generalPatientAdvice">
              <p>Patient or carers should be given advice on how to administer potassium chloride modified-release tablets.</p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Safe practice</h3>
              <p>Potassium overdose can be fatal. Ready-mixed infusion solutions containing potassium should be used. Exceptionally, if potassium chloride concentrate is used for preparing an infusion, the infusion solution should be <b>thoroughly mixed</b>. Local policies on avoiding inadvertent use of potassium chloride concentrate should be followed.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With intravenous use:</strong>
            seek specialist advice in very severe potassium depletion or difficult cases
          </li>
          <li>
              <strong>With oral use:</strong>
            cardiac disease
          </li>
          <li>
              <strong>With oral use:</strong>
            elderly
          </li>
          <li>
              <strong>With oral use:</strong>
            hiatus hernia (<i>with modified-release preparations</i>
          </li>
          <li>
              <strong>With oral use:</strong>
            history of peptic ulcer (<i>with modified-release preparations</i>)
          </li>
          <li>
              <strong>With oral use:</strong>
            intestinal stricture (<i>with modified-release preparations</i>)
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Regular monitoring of plasma-potassium concentration is essential in those taking potassium supplements.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>ECG monitoring should be performed in difficult cases.</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
                <p class="title">Potassium Tablets</p>
              <p>Do not confuse Effervescent Potassium Tablets BPC 1968 with effervescent potassium chloride tablets. Effervescent Potassium Tablets BPC 1968 do not contain chloride ions and their use should be restricted to hyperchloraemic states.</p>
            </section>
      </section>



      <section class="tab-pane" id="lessSuitableForPrescribing">
        <h2>Conditions when less suitable for prescribing</h2>

            <section class="lessSuitableForPrescribing">
              <p>Modified-release tablets are less suitable for prescribing.</p><p>Modified-release preparations should be avoided unless effervescent tablets or liquid preparations inappropriate.</p>
            </section>
      </section>






      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of POTASSIUM CHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            solution for infusion,
            oral solution,
            infusion,

            <div id="PHP74587"><a href="../medicinalForm/PHP74587.html" data-target="#PHP74587" data-action="load">Oral solution</a></div>
            <div id="PHP74592"><a href="../medicinalForm/PHP74592.html" data-target="#PHP74592" data-action="load">Solution for infusion</a></div>
            <div id="PHP77990"><a href="../medicinalForm/PHP77990.html" data-target="#PHP77990" data-action="load">Not applicable</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
